Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence.

MLA

Chabre, Olivier, et al. “Osilodrostat for the Treatment of Cushing’s Disease: Efficacy, Stability, and Persistence.” The Lancet. Diabetes & Endocrinology, vol. 10, no. 6, June 2022, pp. 384–85. EBSCOhost, https://doi.org/10.1016/S2213-8587(22)00134-6.

APA

Chabre, O., Muller, M., Cristante, J., Cracowski, J.-L., & Gay, E. (2022). Osilodrostat for the treatment of Cushing’s disease: efficacy, stability, and persistence. The Lancet. Diabetes & Endocrinology, 10(6), 384–385. https://doi.org/10.1016/S2213-8587(22)00134-6

Chicago

Chabre, Olivier, Marie Muller, Justine Cristante, Jean-Luc Cracowski, and Emmanuel Gay. 2022. “Osilodrostat for the Treatment of Cushing’s Disease: Efficacy, Stability, and Persistence.” The Lancet. Diabetes & Endocrinology 10 (6): 384–85. doi:10.1016/S2213-8587(22)00134-6.